RE
AKBA icon

RBC Europe’s Akebia Therapeutics AKBA Stock Holding History

RBC Europe’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-355
Closed -$1.72K – 1059
2019
Q2 		$1.72K Hold
355
– – ﹤0.01% 990
2019
Q1 		$2.91K Hold
355
– – ﹤0.01% 975
2018
Q4 		$1.96K Buy
+355
New +$2.78K ﹤0.01% 1003

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBC Europe's AKBA Position: Q3 2019 in Review

RBC Europe sold out of Akebia Therapeutics (AKBA) in Q3 2019, closing a stake of 355 shares — an estimated $1.72K sold.

RBC Europe first reported a position in AKBA in Q4 2018 and held it in 3 quarters. The position peaked at $2.91K in Q1 2019. 150 funds tracked by Wall St. Rank hold AKBA as of Q3 2019.

  • RBC Europe reported no remaining Akebia Therapeutics position as of Q3 2019 after selling out during the quarter.
  • RBC Europe sold 355 Akebia Therapeutics shares in Q3 2019, an estimated $1.72K.
  • RBC Europe first reported a position in Akebia Therapeutics in Q4 2018 and held it in 3 quarters.
  • RBC Europe's Akebia Therapeutics position peaked at $2.91K in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2019.

Based on RBC Europe's 13F filing for Q3 2019, filed 9 Nov 2023.